Immune checkpoint inhibitors suppress hepatitis c virus replication in infected patients with solid tumors

Marcel Yibirin,Khalis Mustafayev,Jeff Hosry,Pooja Pundhir,Joseph Klingen,Eduardo Yepez-Guevara,Bruno Granwehr,Ahmed Omar Kaseb,Aung Naing,Sapna Patel,Amishi Y. Shah,Ferdinandos Skoulidis,Hussein A. Tawbi,Lan S. Wang,Ethan D. Miller,Hao Chi Zhang,Amado Zurita-Saavedra,Harrys A. Torres

HEPATOLOGY（2022）

引用 1|浏览9

暂无评分

摘要

Inhibition of HCV replication with virologic cure can develop in patients receiving ICIs without DAAs. HCV reactivation occurs primarily in patients receiving immunosuppressants for ICI-related toxic effects. ICIs are safe in HCV-infected patients with solid tumors. Chronic HCV infection should not be considered a contraindication for ICI therapy.

查看译文

关键词

hepatitis,solid tumors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要